ESCRS - KAMRA results

KAMRA results

KAMRA results

Four-year follow-up with the AcuFocus ACI-7000, now known as the KAMRA, intracorneal inlay suggest long-term safety and efficacy for the device.  A study of 39 presbyopic patients aged 45-60 years showed lasting improvement in uncorrected near visual acuity, with most patients able to read J3 or better. Uncorrected distance acuity was 20/40 or better in all patients. Four inlays were explanted during the study. Reasons included refractive shift, thin flap and detection of a buttonhole flap. There were no severe corneal complications that affected final vision.

Ö Yılmaz et al., JCRS, “Intracorneal inlay to correct presbyopia: Long-term results,†Volume 37, No. 7, 1275-1281.

Latest Articles
Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

Diamonds in the Rough

The push for inclusivity in ophthalmology.

Read more...

Making Female Leadership More than a Moment

A remarkable global confluence of women in key positions.

Read more...

ESCRS Talks Technology at AAO

Europe adopts technological advances, US still waiting for lenses and lasers.

Read more...

Sorting Out Simultaneous Vision IOLs

The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.

Read more...

Big Advantages to Small-Aperture IOLs

Small-aperture IOLs offer superior image quality with increased range of focus.

Read more...

Prioritising Self-Care

Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.

Read more...

Valuing Clinical Trial Design

How inclusivity and diversity can enhance scientific accuracy in research.

Read more...

Knowing Iris Repair: Using Iridodiathermy in Iris Surgery

Prepare for decentred pupils and uneven irides in multiple situations.

Read more...

Neuroprotectant Treatment for MacTel Type 2

Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.

Read more...